What is Amber TX?
Amber Therapeutics operates at the intersection of bioelectronics and clinical medicine, focusing on the development of adaptive neuromodulation therapies. The company's core innovation, the Picostim System, represents a sophisticated approach to treating mixed urinary incontinence by interacting directly with the pudendal nerve. By utilizing a fully implantable device that dynamically adjusts to individual physiological responses, Amber TX is moving beyond traditional, static treatment modalities. This technology addresses a substantial market gap, targeting a condition that affects millions of women globally, yet remains historically underserved by current medical device standards. The company's multidisciplinary team leverages deep expertise in neuro-engineering to transform patient outcomes.
How much funding has Amber TX raised?
Amber TX has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2024): $100M with participation from Lightstone Ventures, New Enterprise Associates, and F-Prime Capital Partners
Key Investors in Amber TX
Lightstone Ventures
Lightstone Ventures backs founders turning cutting edge science into new therapies and medical technologies, providing capital and strategic insight to transform lab ideas into patient treatments.
New Enterprise Associates
Established in 1977, NEA is a prominent venture capital firm focused on partnering with entrepreneurs to build transformative businesses across various technology and healthcare sectors.
F-Prime Capital Partners
F-Prime Capital is a team of investors, engineers, and scientists dedicated to investing in healthcare and technology, leveraging deep domain expertise to support high-growth companies.
What's next for Amber TX?
Following this major enterprise-level funding, Amber TX is expected to prioritize the expansion of its clinical trial infrastructure and the optimization of its manufacturing processes. The strategic focus will likely shift toward securing regulatory milestones and preparing for commercialization, ensuring that the Picostim System can be integrated into standard clinical practice. As the company matures, the emphasis will remain on demonstrating long-term efficacy and safety data to support broader adoption. By maintaining a rigorous focus on technical innovation and clinical validation, Amber TX is poised to establish a new standard of care in the neuromodulation space, potentially expanding its therapeutic reach to other pelvic health indications in the future.
See full Amber TX company page
